Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Target A MGD
- Development stage
- Preclinical
- Lead developer
- Txinno Bioscience
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Target A MGD is a drug discovery program by Txinno Bioscience that utilizes a molecular glue degrader (MGD) approach to target an undisclosed biological entity, referred to as Target A. This target is associated with intrinsic cancer vulnerabilities, and the program aims to develop small molecule therapeutics that induce the degradation of this target protein by facilitating its recruitment to an E3 ubiquitin ligase. While the program is a key component of Txinno's oncology strategy, specific details regarding the identity of Target A or the development of a lead clinical candidate have not been publicly disclosed.
- Other names
- Target A MGD
02
Targets
ENPP1
Beyond the preview
Go deeper on Target A MGD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Target A MGD.